Pérez-Fidalgo J A, Vila Arteaga J, Chirivella González I, Martínez Belda R, Bermejo de Lasheras B, Roselló Keranën S, Fons Moreno A, Lluch Hernández A
Servicio de Oncología y Oftalmología, Hospital Clínico Universitario, Valencia, Spain.
An Med Interna. 2008 Apr;25(4):178-80. doi: 10.4321/s0212-71992008000400006.
The 4-5% of the breast cancer patients have metastases in the eye. We present the case of a 30-year-old woman with an infiltrant duct carcinoma of the breast pT2N2M0 HER2 positive. Six months after primary radical treatment she had a systemic relapse with multiples metastatic sites, so several treatment with trastuzumab in combination with chemotherapy were started. After 4 years patient presented multiple white-coloured micronodules in the iris of the right eye. Only a 3-7.8% of ocular metastases are located in the iris. With mantenaince therapy with trastuzumab natural history of the illness has changed. Several studies had analyzed if metastases in the brain during treatment with trastuzumab have increased in comparison with the pretrastuzumab era. The infrequent presentation of metastases in the anterior uveal makes difficult to establish if it is an spontaneous fact or if it is favoured by trastuzumab treatment.
4%至5%的乳腺癌患者会出现眼部转移。我们报告了一例30岁女性,患有乳腺浸润性导管癌,pT2N2M0,HER2阳性。在进行初次根治性治疗6个月后,她出现了全身性复发,有多个转移部位,因此开始了曲妥珠单抗联合化疗的多次治疗。4年后,患者右眼虹膜出现多个白色小结节。仅有3%至7.8%的眼部转移位于虹膜。随着曲妥珠单抗维持治疗,疾病的自然病程发生了改变。多项研究分析了与曲妥珠单抗治疗前的时代相比,在使用曲妥珠单抗治疗期间脑转移是否有所增加。前葡萄膜转移的罕见表现使得难以确定这是一个自发现象还是受曲妥珠单抗治疗的影响。